OncoTargets and Therapy (Aug 2021)
A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer
Abstract
Suxing Liu,1 Di Li,1 Jian Liu,2 Huiyun Wang,1 Ivana Horecny,1 Ru Shen,1 Rumin Zhang,1 Heping Wu,2 Qiyue Hu,3 Peng Zhao,2 Fengqi Zhang,2 Yinfa Yan,2 Jun Feng,4 Linghang Zhuang,2 Jing Li,1 Lianshan Zhang,5 Weikang Tao5 1Department of Biology, Eternity Bioscience Inc., Cranbury, NJ, 08512, USA; 2Department of Chemistry, Eternity Bioscience Inc., Cranbury, NJ, 08512, USA; 3Department of Molecular Modeling, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People’s Republic of China; 4Department of Process Chemistry, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People’s Republic of China; 5R&D Center, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People’s Republic of ChinaCorrespondence: Suxing LiuDepartment of Biology, Eternity Bioscience Inc, 6 Cedarbrook Drive, Cranbury, NJ, 08512, USAEmail [email protected]: CD73 and adenosine support growth-promoting neovascularization, metastasis, and survival in cells, and promote anti-PD-1 mAb therapy-induced immune escape. Consequently, developing a CD73 inhibitor as monotherapy and a potential beneficial combination partner with immune-checkpoint inhibitors needs investigation.Methods: CD73 inhibitors were evaluated in vitro with soluble and membrane-bound CD73 enzymes, as well as its PD biomarker responses in human peripheral blood mononuclear cells (PBMC) by flow cytometry and ELISA. The binding modes of the molecules were analyzed via molecular modeling. The anti-tumor activity and synergistic effect of SHR170008 in combination with anti-PD-1 mAb were evaluated in a syngeneic mouse breast cancer model.Results: SHR170008 was discovered during the initial structural modifications on the link between the ribose and the α-phosphate of AMPCP, which significantly improved the stability of the compound confirmed by the metabolite identification study. Further modifications on the adenine base of AMPCP improved the potency due to forming stronger interactions with CD73 protein. It exhibited potent inhibitory activities on soluble and endogenous membrane-bound CD73 enzymes, and induced IFNγ production, reversed AMP-suppressed CD25+ and CD8+/CD25+ expression, and enhanced granzyme B production on CD8+ T cells in human PBMC. SHR170008 showed dose-dependent anti-tumor efficacy with suppression of adenosine in the tumors in EMT6 mouse breast tumor model. The increase of adenosine in tumor tissue by anti-PD-1 mAb alone was suppressed by SHR170008 in the combination groups. Simultaneous inhibition of CD73 and PD-1 neutralization synergistically enhanced antitumor immunity and biomarkers in response, and exposures of SHR170008 were correlated with the efficacy readouts.Conclusion: Our findings suggest that CD73 may serve as an immune checkpoint by generating adenosine, which suppresses the antitumor activity of anti-PD-1 mAb, and inhibition of CD73 may be a potential beneficial combination partner with immune-checkpoint inhibitors to improve their therapeutic outcomes in general.Keywords: small-molecule inhibitor of CD73, adenosine, anti-PD-1 mAb, checkpoint blockade, immunotherapy, combination therapy
